Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant intercalated gefitinib plus chemotherapy versus chemotherapy alone in EGFR-mutant resected non-squamous NSCLC
KCT0003069Phase 3Completed
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib, pemetrexed, cisplatin, vinorelbine in non-small cell lung cancer (NSCLC), sponsored by Samyang Biopharmaceuticals Corporation. Started Apr 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0003069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003069.